Latest Ulcerative colitis Stories
PRINCETON, N.J., Nov. 8, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its program for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate pediatric Crohn's disease has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA). Soligenix has also previously received Orphan Drug...
CAMBRIDGE, Mass., Oct. 31, 2012 /PRNewswire/ -- ViThera Pharmaceuticals, Inc, a developer of novel therapeutics based on engineered probiotic bacteria, announced today the publication of breakthrough data validating its approach for the delivery of elafin in treating gastrointestinal inflammation. The results were published today by the journal Science Translational Medicine and show use of recombinant probiotic and non-pathogenic food-strain bacteria to deliver elafin, a protein...
NEW YORK, Oct. 30, 2012 /PRNewswire/ -- The Jeffrey Epstein VI Foundation has backed the largest collaborative study of Crohn's and Colitis Disease in children. The study, called the Kids Pediatric Network, was initiated by the Crohn's and Colitis Foundation of America. The Jeffrey Epstein VI Foundation was founded by the prominent science philanthropist, Jeffrey Epstein in 2000. The foundation is known to support cutting edge scientific research around the world and financed the...
Provide new insights on Infliximab use, disease characteristics, fistulizing Crohn's disease Three separate studies presented today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas help to advance understanding of the differences between African American and Caucasian patients with Inflammatory Bowel Disease (IBD) and provide clinicians with new insight on how racial disparities involving disease characteristics, infliximab use, and...
AMSTERDAM, October 22, 2012 /PRNewswire/ -- The results of an international survey to assess patients' and healthcare professionals' (HCPs') differing perceptions of ulcerative colitis have been presented at a Shire organised press briefing during the 20th United European Gastroenterology Week (UEGW) meeting in Amsterdam today. The 'Mind the Gap' survey, which was sponsored by Shire, is the first international study in ulcerative colitis (UC) to compare the views and beliefs...
LAS VEGAS, Oct. 22, 2012 /PRNewswire/ -- New Phase 3 study findings showed significantly more patients with moderately to severely active ulcerative colitis (UC) who responded to induction therapy with subcutaneously administered SIMPONI(®) (golimumab) maintained clinical response through week 54, the primary endpoint of the study, compared with patients receiving placebo. Investigators will report clinical response, clinical remission and mucosal healing results through one year...
ATLANTA, Oct. 18, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology and neuroscience treatment and research, is marking the 2012 American College of Gastroenterology (ACG) Annual Scientific meeting in Las Vegas, Nevada by reinforcing its commitment to improving the lives of patients with Crohn's disease. UCB will present scientific data at this year's ACG meeting, October 19-24. "The annual ACG meeting gives UCB the opportunity to demonstrate our...
According to court documents, on June 1st, 2012, the lawsuit of Andrew Boatright v Hoffman-La Roche was removed by the defendants to federal court (case no. 2:2012cv03115, Pennsylvania Eastern District Court). Plaintiff claims he was diagnosed with Crohn’s disease after taking Accutane. Accutane (isotretinoin), a popular acne medication, was introduced in 1982 and in 2009 as the number of lawsuits against Hoffman-LaRoche kept increasing the drug was pulled from the US market. Now,...
Scientists from the Florida campus of The Scripps Research Institute have developed a novel technology that can identify, in animal models, potential biomarkers of ulcerative colitis, a type of inflammatory bowel disease that affects the lining of the colon. The study was published October 3, 2012, in the Journal of the American Chemical Society. The new research focuses on the protein arginine deiminases (PAD), which have been implicated in a number of diseases, including cancer,...
Michigan State University researchers have unlocked secrets in bone marrow that could lead to improved treatments for colitis and Crohn’s disease. The results, featured in the current issue of Proceedings of the National Academy of the Sciences, show that the havoc inflammatory bowel diseases wreaks on the digestive tract is mirrored in bone marrow. Early indications also show that the disorders of the gut could potentially be treated through the bone marrow, said Pam Fraker, MSU...
